PO.MCB09.02 · 分子与细胞生物学

Polysulfides contribute to persulfidation of FSCN-1 to accelerate development of pancreatic ductal adenocarcinoma

编号 7315 展板 1 时间 4/22 09:00–12:00 区域 Section 23 主讲 Makoto Suematsu, MD
分会场 Metabolic Vulnerabilities in Pancreatic, Hepatic, and Renal Cancers
该海报暂无可访问的完整资料 AACR 官方页面 ↗

作者与单位

Makoto Suematsu1, Takehiro Yamamoto1, Minako Takizawa1, Chiyoko Nishime1, Masami Suzuki1, Nobuyoshi Hiraoka2

1Central Institute for Experimental Medicine and Life Science, Kawasaki city, Japan,2Pathology, National Cancer Center Japan, Tokyo, Japan

摘要 Abstract

We previously reported polysulfides (PS) are overgenerated in ovarian and breast cancers that contribute to worsening prognosis and chemoresistance (1, 2), while molecular mechanisms remain unknown. In this study, expression of PS-generating enzymes in post-operative pancreatic ductal adenocarcinoma (PDAC) tissues were examined immunohistochemically using FFPE samples from 120 Japanese patients. Analyses revealed that cystathionine gamma-lyase (CSE) expressed in cancer-associated fibroblasts (CAF) serves as an independent factor worsening post-operative disease-free and overall survivals. CSE-positive CAF predominantly occurs in regions adjacent to cancer cells and activated glycolysis to deliver C1 units towards transsulfudation as judged by elevated methylation of PFKFB3 and PKM2 that activates the carbon delivery for serine-cysteine synthesis. Gold nanoparticle-based surface-enhanced Raman spectroscopy (SERS) imaging (3) using frozen PDAC tissues unveiled PS generation over the cancer tissues. PS renders cancer cells to induce site-specific persulfidation of fascin-actin-bundling protein (FSCN)-1 to stimulate the ability of cancer cells to migrate, while PS-degrading ambroxol or gemcitabine canceled the effects through their action to scavenge PS in vitro. These results suggest that PS serves as a marker inducing CAF-mediated cancer invasiveness.References (1) Yamamoto T, et al. Cancer Res (2024)(2) Honda K, et al. Redox Biol (2021)(3) Shiota M, et al. Nature Commun (2018)
利益披露 Disclosure
M. Suematsu, None.. T. Yamamoto, None.. M. Takizawa, None.. C. Nishime, None.. M. Suzuki, None.. N. Hiraoka, None.

在会议检索中打开